Immunophenotype of multiple myeloma and its prognosis value
CAI Xiao-hui, LIU Bo, WANG Lin-xian, HUANG Yu-mei, JIANG Yuan, HUANG Hong-jun, WU Bai-ping
Department of Clinical Laboratory, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China
Abstract：Objective To explore the immunophenotype characteristics of myeloma cells in newly diagnosed patients with multiple myeloma (MM) and its prognosis value. Methods Multiparameter flow cytometry was used to detect the immunophenotypes of myeloma cells in 49 newly diagnosed MM patients. The clinical data about the patients’ prognosis were collected and statistically analyzed. Results Myeloma cells were detected in all the patients, and the positive rates of CD45, CD38, CD138, CD19 and CD56 were 8.16%, 100%, 89.80%, 6.12% and 42.86% respectively. The concentrations of serum β2-microglobulin (β2-MG) in the CD45-negative patients were higher than those in CD45-positive patients (P<0.05). The levels of hemoglobin (Hb) and albumin (ALB) in CD19-negative patients were lower than those in CD19-positive patients (P<0.05). The proportion of myeloma cells in bone marrow of CD56-negative patients was higher than that of CD56-positive patients (P<0.05). However,no significant correlation was observed between the expression of CD138 and the proportion of myeloma cells, serum β2-MG, Alb, Hb and calcium. Conclusions Determination of the immunophenotype of multiple myeloma is conducive to its clinical diagnosis. CD45, CD19 and CD56 deficiencies may induce poor prognosis. Immunophenotype determination is of great significance in guiding therapy and predicting prognosis of multiple myeloma.
[1] Ruiz GJ. Cell surface markers in multiple myeloma[J]. Mayo Clinic Proceedings, 1994, 69(7):684-690. [2] Sakalová A, Holománová D, Mikulecky M, et al. Prognostic value of plasma-cell immunophenotype in patients with multiple myeloma[J]. Neoplasma, 1993, 40(6):351-354. [3] 李翰卿,翟勇平.流式细胞术检测多发性骨髓瘤免疫表型和残留病灶的研究进展[J].中国实验血液学杂志,2015,23(1):241-245. [4] 王亚哲,刘艳荣,常艳,等. 237例多发性骨髓瘤的免疫表型分析及其在微小残留病检测中的应用[C].第12届全国实验血液学会议论文摘要,2009. [5] 杨佳,杨波,张丽.多发性骨髓瘤细胞形态分型与流式细胞术检测抗原表达相关性研究[J].中华细胞与干细胞杂志,2012,2(2):107-110. [6] Kumar S, Rajkumar SV, Kimlinger T, et al. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations[J]. Leukemia, 2005,19(8):1466-1470. [7] Mateo G, Montalbán MA, Vidriales MB, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy[J]. J Clinic Oncol, 2008, 26(16):2737-2744. [8] Lovell R, Dunn JA, Begum G, et al. Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival[J]. Brit J Haematol, 2005, 130(4):542-548. [9] Mahmoud MS, FujⅡ R, Ishikawa H, et al. Enforced CD19 expression leads to growth inhibition and reduced tumorigenicity[J]. Blood, 1999, 94(10):3551-3558. [10] Naohi S, Akihiro T, Kazuyuki S, et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma[J]. Brit J Haematol, 2002, 117(4):882-885. [11] Smock KJ, Perkins SL, Bahler DW. Quantitation of plasma cells in bone marrow aspirates by flow cytometric analysis compared with morphologic assessment[J]. Arch Pathol Lab Med, 2007, 131(6):951-955.
2016, Vol. 23 
